Intervention
Androgen deprivation therapy
ClinicalTrials.gov intervention label
Clinical trials
18 shownTreatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional ImagingNCT06276465 · 2024-10-07
RECRUITINGImplementation of Precision Medicine in High-risk Prostate CancerNCT06687421 · 2024-06-10
RECRUITINGMetastasis-directed Therapy for Oligorecurrent Prostate CancerNCT05352178 · 2022-04-20
RECRUITINGADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)NCT04916613 · 2022-04-19
RECRUITINGAPACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate CancerNCT06709326 · 2020-09-29
RECRUITINGTrial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical ProstatectomyNCT05746806 · 2023-03-29
ACTIVE_NOT_RECRUITINGImaging and Genomic Biomarkers to Predict Response in Prostate CancerNCT05477823 · 2023-03-08
ACTIVE_NOT_RECRUITINGAdaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate CancerNCT05628363 · 2023-01-18
ACTIVE_NOT_RECRUITINGEfficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate CancerNCT05249712 · 2022-01-01
UNKNOWNFlibanserin in Men Receiving Androgen Suppression for Prostate CancerNCT04743934 · 2021-07-02
COMPLETEDFluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialNCT05223582 · 2021-05-01
UNKNOWNAnalysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA TrialNCT05188911 · 2020-07-15
UNKNOWNAbiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelNCT03419234 · 2018-04-26
ACTIVE_NOT_RECRUITINGStudy on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerNCT02918968 · 2016-11-02
COMPLETEDEXTEND Exercise TrialNCT02256111 · 2015-05-13
COMPLETEDComparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer PatientsNCT02303327 · 2015-01-01
ACTIVE_NOT_RECRUITINGEfficacy Study Evaluating Chemotherapy in Prostate CancerNCT01978873 · 2012-11-01
UNKNOWNProspective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate CancerNCT00455624 · 2002-11-01
COMPLETEDCommon conditions
Prostate Cancer11Prostate Cancer Metastatic2Cancer of the Prostate1Castration Levels of Testosterone1Castration-resistant Prostate Cancer1Castration-Resistant Prostate Carcinoma1High-risk Prostate Cancer1Hormone Sensitive Prostate Cancer1Metastatic Cancer1Metastatic Disease1Metastatic Prostate Carcinoma in the Soft Tissue1Neoadjuvant Therapy1Non-metastatic, Hormone naïve Prostate Cancer1Oligometastasis1Oligometastatic Disease1Prostate Adenocarcinoma1Prostate Cancer Recurrent1Prostate Carcinoma Metastatic in the Bone1Prostatic Cancer, Castration-Resistant1Recurrent Prostate Cancer1Stage IV Prostate Adenocarcinoma AJCC v71
Leading sponsors
Fudan University2UNICANCER2Andreas Josefsson1Andrew McDonald1Astellas Pharma Inc1Duke University1ECOG-ACRIN Cancer Research Group1Insel Gruppe AG, University Hospital Bern1Massachusetts General Hospital1Örebro University, Sweden1Sir Mortimer B. Davis - Jewish General Hospital1The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1Umeå University1Universitaire Ziekenhuizen KU Leuven1University of Wisconsin, Madison1
Trial status mix
ACTIVE_NOT_RECRUITING5
RECRUITING5
COMPLETED4
UNKNOWN4
Phase mix
PHASE25
PHASE35
NA3
EARLY_PHASE11
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.